SSII
SS Innovations International, Inc.
Medical - Devices
Market Cap$763M
5Y Perf.+614.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SSII vs RBOT
Revenue, margins, valuation, and 5-year total return — side by side.
RBOT
Vicarious Surgical Inc.
Medical - Devices
Market Cap$3M
5Y Perf.-99.8%
SSII vs RBOT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SSII | RBOT |
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $763M | $3M |
| Revenue (TTM) | $42M | $0.00 |
| Net Income (TTM) | $-12M | $-42M |
| Gross Margin | 46.0% | — |
| Operating Margin | -19.2% | — |
| Total Debt | $3M | $8M |
| Cash & Equiv. | $3M | $3M |
SSII vs RBOT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SSII
RBOT
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| SS Innovations Inte… (SSII) | 100 | 714.5 | +614.5% |
| Vicarious Surgical … (RBOT) | 100 | 0.2 | -99.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SSII vs RBOT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SSII leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Vicarious Surgical Inc. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
SSII
SS Innovations International, Inc.
The Income Pick
SSII carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.01
- Rev growth 105.7%, EPS growth 40.0%, 3Y rev CAGR 207.7%
- 162.0% 10Y total return vs RBOT's -99.8%
Best for: income & stability and growth exposure
RBOT
Vicarious Surgical Inc.
The Quality Compounder
RBOT is the clearest fit if your priority is quality.
- 5.0% margin vs SSII's -28.5%
Best for: quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SSII | 105.7% revenue growth vs RBOT's 31.5% |
| Quality / Margins | RBOT | 5.0% margin vs SSII's -28.5% |
| Stability / Safety | SSII | Beta 0.01 vs RBOT's 1.92, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SSII | -61.3% vs RBOT's -94.1% |
| Efficiency (ROA) | SSII | -17.5% ROA vs RBOT's -164.5%, ROIC -17.7% vs -116.2% |
SSII vs RBOT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
SSII vs RBOT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSSIILAGGINGRBOT
RBOTVicarious Surgical In…
0leads
SSIISS Innovations Intern…
4leads
6 Total Categories
CATEGORYLEADERvs RBOTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SSII1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SSII8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
SSII6/6
Risk & VolatilityBeta, volatility, and downside exposure
SSII2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SSII leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SSII and RBOT operate at a comparable scale, with $42M and $0 in trailing revenue.
| Metric | SSIISS Innovations In… | RBOTVicarious Surgica… |
|---|---|---|
| RevenueTrailing 12 months | $42M | $0 |
| EBITDAEarnings before interest/tax | -$7M | -$42M |
| Net IncomeAfter-tax profit | -$12M | -$42M |
| Free Cash FlowCash after capex | -$22M | -$40M |
| Gross MarginGross profit ÷ Revenue | +46.0% | — |
| Operating MarginEBIT ÷ Revenue | -19.2% | — |
| Net MarginNet income ÷ Revenue | -28.5% | — |
| FCF MarginFCF ÷ Revenue | -52.3% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +158.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +69.0% | +58.1% |
SSII leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SSII and RBOT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SSIISS Innovations In… | RBOTVicarious Surgica… |
|---|---|---|
| Market CapShares × price | $763M | $3M |
| Enterprise ValueMkt cap + debt − cash | $763M | $8M |
| Trailing P/EPrice ÷ TTM EPS | -65.50x | -0.06x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 17.96x | — |
| Price / BookPrice ÷ Book value/share | 20.43x | 0.30x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SSII and RBOT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
SSII leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
SSII delivers a -30.2% return on equity — every $100 of shareholder capital generates $-30 in annual profit, vs $-3 for RBOT. SSII carries lower financial leverage with a 0.08x debt-to-equity ratio, signaling a more conservative balance sheet compared to RBOT's 0.79x. On the Piotroski fundamental quality scale (0–9), SSII scores 5/9 vs RBOT's 1/9, reflecting solid financial health.
| Metric | SSIISS Innovations In… | RBOTVicarious Surgica… |
|---|---|---|
| ROE (TTM)Return on equity | -30.2% | -3.3% |
| ROA (TTM)Return on assets | -17.5% | -164.5% |
| ROICReturn on invested capital | -17.7% | -116.2% |
| ROCEReturn on capital employed | -23.6% | -134.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 1 |
| Debt / EquityFinancial leverage | 0.08x | 0.79x |
| Net DebtTotal debt minus cash | -$289,540 | $5M |
| Cash & Equiv.Liquid assets | $3M | $3M |
| Total DebtShort + long-term debt | $3M | $8M |
| Interest CoverageEBIT ÷ Interest expense | -7.35x | — |
SSII leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
SSII leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SSII five years ago would be worth $38,155 today (with dividends reinvested), compared to $16 for RBOT. Over the past 12 months, SSII leads with a -61.3% total return vs RBOT's -94.1%. The 3-year compound annual growth rate (CAGR) favors SSII at 82.1% vs RBOT's -80.2% — a key indicator of consistent wealth creation.
| Metric | SSIISS Innovations In… | RBOTVicarious Surgica… |
|---|---|---|
| YTD ReturnYear-to-date | -30.4% | -80.6% |
| 1-Year ReturnPast 12 months | -61.3% | -94.1% |
| 3-Year ReturnCumulative with dividends | +503.7% | -99.2% |
| 5-Year ReturnCumulative with dividends | +281.6% | -99.8% |
| 10-Year ReturnCumulative with dividends | +162.0% | -99.8% |
| CAGR (3Y)Annualised 3-year return | +82.1% | -80.2% |
SSII leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
SSII leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SSII is the less volatile stock with a 0.01 beta — it tends to amplify market swings less than RBOT's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SSII currently trades 33.1% from its 52-week high vs RBOT's 3.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SSIISS Innovations In… | RBOTVicarious Surgica… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.01x | 1.92x |
| 52-Week HighHighest price in past year | $11.87 | $13.75 |
| 52-Week LowLowest price in past year | $3.02 | $0.35 |
| % of 52W HighCurrent price vs 52-week peak | +33.1% | +3.6% |
| RSI (14)Momentum oscillator 0–100 | 39.1 | 30.0 |
| Avg Volume (50D)Average daily shares traded | 54K | 24K |
SSII leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SSIISS Innovations In… | RBOTVicarious Surgica… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SSII leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallSS Innovations Internationa… (SSII)Leads 4 of 6 categories
Loading custom metrics...
SSII vs RBOT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — SSII or RBOT?
Over the past 5 years, SS Innovations International, Inc.
(SSII) delivered a total return of +281. 6%, compared to -99. 8% for Vicarious Surgical Inc. (RBOT). Over 10 years, the gap is even starker: SSII returned +162. 0% versus RBOT's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — SSII or RBOT?
By beta (market sensitivity over 5 years), SS Innovations International, Inc.
(SSII) is the lower-risk stock at 0. 01β versus Vicarious Surgical Inc. 's 1. 92β — meaning RBOT is approximately 13245% more volatile than SSII relative to the S&P 500. On balance sheet safety, SS Innovations International, Inc. (SSII) carries a lower debt/equity ratio of 8% versus 79% for Vicarious Surgical Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — SSII or RBOT?
On earnings-per-share growth, the picture is similar: SS Innovations International, Inc.
grew EPS 40. 0% year-over-year, compared to 21. 2% for Vicarious Surgical Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — SSII or RBOT?
Vicarious Surgical Inc.
(RBOT) is the more profitable company, earning 0. 0% net margin versus -28. 5% for SS Innovations International, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RBOT leads at 0. 0% versus -19. 2% for SSII. At the gross margin level — before operating expenses — SSII leads at 43. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SSII or RBOT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is SSII or RBOT better for a retirement portfolio?
For long-horizon retirement investors, SS Innovations International, Inc.
(SSII) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), +162. 0% 10Y return). Vicarious Surgical Inc. (RBOT) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSII: +162. 0%, RBOT: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SSII and RBOT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SSII is a small-cap high-growth stock; RBOT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.